Talazoparib Before Standard Therapy in Treating Patients With Invasive, BRCA-Mutated Breast Cancer

NCT02282345 | Completed Phase 2 Results FDA Drug

• 2 other identifiers: 2014-0045NCI-2015-00335
• Study Type: interventional
• Target: 36
• Locations: 1 country
• Sites: 1

Brief Summary

This phase II trial studies the side effects of talazoparib when given before standard therapy in treating patients with breast cancer that has spread to nearby healthy tissue and has a mutation in a breast cancer, early onset (BRCA) gene. Talazoparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth, and may be especially effective in patients with BRCA mutations. It is not yet known whether adding talazoparib before standard treatment is safe in treating patients with BRCA mutated breast cancer.

Conditions

Breast Adenocarcinoma; Deleterious BRCA1 Gene Mutation; Deleterious BRCA2 Gene Mutation; HER2/Neu Negative; Invasive Breast Carcinoma

Outcome Measures

Primary Outcomes (2)

• Number of Participants With Overall Pathological Complete Response (pCR)

  Pathologic response was documented using the Residual Cancer Burden (RCB) Calculator. Residual cancer burden by ICR will be reported as a categorical variable with four classes (categories) RCB 0 (pCR) which correlates to no invasive disease in breast and lymph, I (minimal RCB), II (moderate RCB), and III (extensive RCB). Up to two fine needle aspirates (FNAs) will also be obtained at each time point for a total of up to 6 FNA's for the trial, which will be used for the patient derived xenograft models. Pre-study biopsies, as well as biopsies within 7 days prior to the completion of 2 months of talazoparib will be collected via diagnostic imaging. During the expansion phase of this trial, ultrasounds will be obtained every 2 cycles (+/- 1 week). Therapy will be discontinued if the Physician or PI indicates clinically significant progression of disease.

  Up to 6 months

• Number of Participants With Grade 4 Toxicities

  To assess the toxicity profile of women taking single agent Talazoparib prior to surgery. If greater than 33% of the patients enrolled have either a grade 4 toxicity possibly, probably, or definitely related to the treatment as attributed by the Principal Investigator, or requires a delay in treatment for greater than 4 weeks due to toxicity.

  up to 6 months

Secondary Outcomes (1)

• Median Clinical Response to Single Agent Talazoparib

  2 months

Study Arms (1)

Treatment (talazoparib)

EXPERIMENTAL

Patients receive talazoparib PO QD on days 1-28. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then proceed to the standard of care therapy of the treating physician's choice. This arm was concluded early after 13 patients. An expansion arm of 20 patients was opened in August 2016 to include at least 4 and up to 6 cycles of talazoparib, followed by surgery to estimate residual cancer burden after therapy with single-agent talazoparib.

Other: Laboratory Biomarker Analysis; Drug: Talazoparib

Interventions

Laboratory Biomarker Analysis OTHER

Correlative studies

Treatment (talazoparib)

Talazoparib DRUG

Given PO

Also known as: BMN 673, BMN-673

Treatment (talazoparib)

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Signed written informed consent
• Histologically confirmed primary invasive adenocarcinoma of the breast with the size of the primary tumor being at least 1 cm on imaging by either mammography, ultrasound or breast magnetic resonance imaging (MRI)
• Negative human epidermal growth factor receptor 2 (HER-2)/neu- disease defined as patients with fluorescence in situ hybridization (FISH) ratio \< 2.0 or \< 6.0 HER2 gene copies per nucleus, and IHC staining scores of 0, 1+, or 2+
• No treatment for current primary invasive adenocarcinoma of the breast such as irradiation, chemotherapy, immunotherapy, investigational therapy or surgery; previous treatment for breast and/or ovarian cancer with chemotherapy, endocrine therapy, surgery and radiation are allowed if \>= 3 years prior to current diagnosis and there is no clinical evidence of metastatic disease
• Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
• Baseline multi gated acquisition scan (MUGA) or echocardiogram scans with left ventricular ejection fraction (LVEF) of \> 50%
• Absolute neutrophil count (ANC) \>= 1,500/uL
• Platelets \>= 100,000/uL
• Hemoglobin (Hgb) \>= 9 g/dL
• Creatinine clearance \> 50 ml/min
• Total bilirubin =\< 1.5 X upper limit of normal (ULN)
• Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \< 2.5 X ULN
• Negative serum or urine pregnancy test for women within 7 days of receiving the first dose of the study medication for women of childbearing potential; women will be considered not of childbearing potential and exempt from pregnancy testing if they are either a) older than 50 and amenorrheic for at least 12 consecutive months following cessation of all exogenous hormonal treatments, or b) have documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy or bilateral salpingectomy, but not tubal ligation
• Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to 8 weeks after the last dose of investigational product; men on study also must be using contraception
• Identified deleterious mutation in BRCA 1 or 2 genes (this does not include variants of uncertain significance)

You may not qualify if:

• Women who are pregnant (including positive pregnancy test at enrollment or prior to study drug administration) or breast-feeding
• Disease free of prior malignancy for \< 3 years with the exception of curatively treated basal carcinoma of the skin or carcinoma in situ of the cervix
• Any other previous antitumor therapies for the current cancer event
• Has had major surgery within 21 days before cycle 1 day 1
• Gastrointestinal tract disease or defect with associated malabsorption syndrome
• Uncontrolled inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis)
• Myocardial infarction within 6 months before starting therapy, symptomatic congestive heart failure (New York Heart Association \> class II), unstable angina, or unstable cardiac arrhythmia requiring medication
• Serious intercurrent infections or non-malignant medical illness that are uncontrolled or the control of which may be jeopardized by this therapy
• Psychiatric disorders or other conditions rendering the subject incapable of complying with the requirements of the protocols
• Unable to take oral medications
• Known to be human immunodeficiency virus positive
• Known active hepatitis C virus, or known active hepatitis B virus
• Concurrent disease or condition that would interfere with study participation or safety, such as any of the following:
• Active, clinically significant infection either grade \> 2 by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v)4.03 or requiring the use of parenteral anti-microbial agents within 14 days before day 1 of study drug
• Clinically significant bleeding diathesis or coagulopathy, including known platelet function disorders

Sponsors & Collaborators

• M.D. Anderson Cancer Center: lead
• National Cancer Institute (NCI): collaborator

Study Sites (1)

M D Anderson Cancer Center

Houston, Texas, 77030, United States

Location

Related Publications (2)

• Kumar T, Hobbs E, Yang F, Chang JT, Contreras A, Cuentas ERP, Garber H, Lee S, Lu Y, Scoggins ME, Adrada BE, Whitman GJ, Arun BK, Mittendorf EA, Litton JK. Tumor Immune Microenvironment Changes by Multiplex Immunofluorescence Staining in a Pilot Study of Neoadjuvant Talazoparib for Early-Stage Breast Cancer Patients with a Hereditary BRCA Mutation. Clin Cancer Res. 2022 Sep 1;28(17):3669-3676. doi: 10.1158/1078-0432.CCR-21-1278.

  PMID: 35736816 DERIVED

• Litton JK, Scoggins ME, Hess KR, Adrada BE, Murthy RK, Damodaran S, DeSnyder SM, Brewster AM, Barcenas CH, Valero V, Whitman GJ, Schwartz-Gomez J, Mittendorf EA, Thompson AM, Helgason T, Ibrahim N, Piwnica-Worms H, Moulder SL, Arun BK. Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant. J Clin Oncol. 2020 Feb 10;38(5):388-394. doi: 10.1200/JCO.19.01304. Epub 2019 Aug 28.

  PMID: 31461380 DERIVED

Related Links

• University of Texas MD Anderson Cancer Center Website

MeSH Terms

Interventions

talazoparib

Results Point of Contact

• Title: Dr. Jennifer Litton,VP, Clinical Research, VP Clinical Research
• Organization: UT MD Anderson Cancer Center

jlitton@mdanderson.org

(713) 792-2817

Study Officials

• Jennifer K Litton

  M.D. Anderson Cancer Center

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: Yes

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 30, 2014
• First Posted: November 4, 2014
• Study Start: April 16, 2015
• Primary Completion: April 26, 2018
• Study Completion: June 7, 2022
• Last Updated: July 6, 2022
• Results First Posted: February 10, 2022

Record last verified: 2022-06

Locations

US (1)